PhD Scientific Days 2025

Pathological and Oncological Sciences II.

Molecular Subtype Switching During Lymphatic Spread in Small Cell Lung Cancer

Előadó neve

Dr. Ferenczy Anita

Neptun code

OCZQZS

Előadó munkahelye

National Korányi Institute of Pulmonology

Előadó telefonszáma

06706723036

Előadó e-mail címe

ferenczyanita@yahoo.com

Az előadás címe

Molecular Subtype Switching During Lymphatic Spread in Small Cell Lung Cancer

Szerző(k) neve és munkahelye

Anita Ferenczy¹, Kristóf Csende², Bence Ferencz¹, Kristiina Boettiger³, Maria Dorothea Pozonec¹, András Lantos¹, Orsolya Pipek⁴, Anna Solta³, Busra Ernhofer³, Viktória László³, Evelyn Megyesfalvi⁵, Karin Schelch³, Veronika Pozonec⁶, Jozef Skarda⁷, Valeria Skopelidou⁸, Zoltán Lohinai⁹, Christian Lang³, Lilla Horváth¹⁰, Katalin Dezső¹¹, János Fillinger¹⁰, Ferenc Rényi-Vámos⁶, Clemens Aigner³, Balázs Döme³, Zsolt Megyesfalvi¹⁰

1: National Korányi Institue of Pulmonology
2: National Institute of Oncology
3: Medical University of Vienna
4: Eotvos Lorand University
5: National Institue of Oncology
6: National Insititute of Oncology
7: Palacký University Olomouc
8: University Hospital Ostrava and Faculty of Medicine University of Ostrava
9: Torokbalint County Institute of Pulmonology
10: National Korányi Institute of Pulmonology
11: Pathology and Experimental Cancer Research

Bemutatás módja

Szóbeli

Szekció

Pathological and Oncological Sciences II.

Language of the presentation

English

Preferred session

Pathological and Oncological Sciences

Összefoglaló szövege

Introduction:
Molecular profiling efforts in small cell lung cancer (SCLC) have predominantly focused on primary tumors, with limited insight into the molecular alterations accompanying lymphatic dissemination. This study systematically investigates the molecular divergence between primary SCLCs and their matched lymph node (LN) metastases, emphasizing subtype dynamics and the expression patterns of clinically pertinent proteins.
Aims:
Our comparative analysis was conducted on 32 surgically resected primary SCLC specimens and their corresponding LN metastases utilizing RNA expression profiling and immunohistochemical (IHC) assessments. Expression levels of SCLC subtype markers (ASCL1, NEUROD1, POU2F3, YAP1) and nine additional cancer-associated proteins were evaluated.
Results:
At the transcriptomic level, no statistically significant differences were observed between primary tumors and matched LN metastases regarding the expression of the selected clinically relevant genes. However, IHC analyses revealed a significantly higher expression of DLL3 in primary tumors relative to LN metastases (p = 0.008). Conversely, NEUROD1 exhibited markedly elevated expression in LN metastases compared to their primary counterparts (p < 0.001). No other proteins demonstrated significant IHC-based expression discrepancies between the two tissue types. Notably, shifts in molecular subtype classification were observed in 21 cases, with evidence of phenotype transitions between neuroendocrine (NE) and non-neuroendocrine (non-NE) states in both ways.
Conclusions:
While the overarching molecular landscape of SCLC LN metastases mirrors that of the primary tumors, critical differences are evident, particularly regarding DLL3 and NEUROD1 expression, as well as subtype plasticity. These findings highlight potential diagnostic pitfalls and underscore the necessity for caution when molecularly characterizing SCLC based solely on LN biopsies, particularly in the context of biomarker-driven clinical trials.

University

Semmelweis University

Supervisor

Zsolt Megyesfalvi

Publication of my abstract

I do not give consent to the publication of my abstract on the website of the congress.

phd.section.field

in doctoral studies after complex exam (PhD)

Kind

Szabad

Status

elfogadva

Accepted presentation method

szóbeli

Előadás fájl jóváhagyás

jóváhagyta

Előadó

9131

Start

12:00

End

12:15